#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2008

INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter)

Delaware0-2622451-0317849(State or other jurisdiction of<br/>incorporation or organization)(Commission File Number)(I.R.S. Employer<br/>Identification No.)

#### 311 Enterprise Drive Plainsboro, NJ 08536 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (609) 275-0500

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### ITEM 8.01 OTHER INFORMATION

On June 3, 2008, Integra LifeSciences Holdings Corporation issued a press release announcing that it has scheduled a conference call for 9:00 AM ET on Thursday, June 5, 2008, to discuss its financial results for the first quarter ended March 31, 2008 and to update forward-looking financial guidance.

Access to the live call is available by dialing 913-312-1487 or through a webcast via a link provided on the Investor Relations homepage of Integra's website at www.Integra-LS.com. Access to a replay is available through June 19, 2008 by dialing 719-457-0820 (PIN 7222524) or through the webcast.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

Exhibit No. Description 99.1 Press Release, dated June 3, 2008, issued by Integra LifeSciences Holdings Corporation.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: June 4, 2008

By: /s/ Stuart M. Essig

Stuart M. Essig President and Chief Executive Officer

# EXHIBIT INDEX

Exhibit No.	Description
 99.1	Press Release, dated June 3, 2008, issued by Integra
55.1	LifeSciences Holdings Corporation.

News Release

Contact:

Integra LifeSciences Holdings Corporation

John B. Henneman III Executive Vice President, Finance and Administration, and Chief Financial Officer (609) 936-2481 jhenneman@Integra-LS.com Karen Mroz-Bremner Senior Manager, Corporate Development and Investor Relations (609) 936-6929 karen.mroz-bremner@Integra-LS.com

Integra LifeSciences to Host First Quarter 2008 Financial Results Conference Call on June 5, 2008

Plainsboro, New Jersey, June 3, 2008-- Integra LifeSciences Holdings Corporation (NASDAQ:IART) has scheduled a conference call for 9:00 AM ET on Thursday, June 5, 2008 to discuss financial results for the first quarter ended March 31, 2008 and to update forward-looking financial guidance. Financial results for the first quarter 2008 will be announced via a news release issued prior to the call.

The conference call will be hosted by Stuart Essig, President and Chief Executive Officer of Integra, and will be open to all listeners. Additional forward-looking information may be discussed in a question and answer session following the call.

Access to the live call is available by dialing 913-312-1487 or through a webcast via a link provided on the Investor Relations homepage of Integra's website at www.Integra-LS.com. Access to a replay is available through June 19, 2008 by dialing 719-457-0820 (PIN 7222524) or through the webcast.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products are used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at (http://www.Integra-LS.com).

IART-G

Source: Integra LifeSciences Holdings Corporation